featured-image

Michail_Petrov-96/iStock via Getty Images SAB Biotherapeutics ( NASDAQ: SABS ) announces a new name , SAB BIO, and a new visual identity, effective immediately. The new brand identity aims to align with its mission to treat and prevent immune and autoimmune disorders using its unique immunotherapy platform. SABS plans to rebrand ahead of a poster presentation at the American Diabetes Association's 84th Scientific Sessions.

The conference will be held in Florida from June 21 through June 24. The rebranding includes a new name, logo mark, and website updates to reflect the company’s strategic evolution; however, the stock symbol will remain SABS. Furthermore, the company also reaffirmed its outlook for fiscal year 2024, as previously disclosed in first quarter earnings, and also confirmed its upcoming milestones, including a topline data readout from its Phase 1 study of its lead candidate, SAB-142.



More on SAB Biotherapeutics: Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics.

Back to Health Page